The U.S. Senate Health Committee will hold a confirmation hearing on Thursday for Dr. Heidi Overton, President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), as lawmakers scrutinize her positions on vaccines, the abortion pill mifepristone, and agency morale amid staffing shortages.
Overton, a preventive medicine physician and deputy director of the White House Domestic Policy Council, has been nominated to replace the agency’s interim leadership following the resignation of former commissioner Dr. Marty Makary in May. The FDA has lost more than 3,000 staff over the past year, including division heads, raising concerns about institutional stability and regulatory independence.
Senate Republicans, led by committee chair Sen. Bill Cassidy (R-La.), are expected to press Overton on her stance regarding the abortion pill mifepristone, which has been a focal point of Republican-led reviews. Cassidy has previously called for tighter restrictions on telemedicine prescriptions and mail-order distribution of the drug, citing safety concerns. The FDA launched a new safety study on mifepristone in June following Cassidy’s requests.
Overton’s confirmation hearing also comes as the FDA faces legal threats from anti-abortion groups. On Thursday, the Students for Life of America (SFLA) filed a notice of intent to sue the agency, alleging that the FDA failed to conduct required environmental testing for mifepristone under the Endangered Species Act. The group argues that the drug’s potential impact on wildlife and waterways was not properly assessed before its 2000 approval. SFLA has 60 days to file a lawsuit if the FDA does not respond to its concerns.
Vaccine Policy Under Scrutiny
Overton’s past statements and White House roles have drawn attention to her views on vaccines. Last month, she participated in an event where Trump signed an executive order to revise the childhood vaccination schedule and split the measles, mumps, and rubella (MMR) vaccine into separate shots. Physicians’ groups and vaccine manufacturers have strongly opposed the order, citing public health risks and logistical challenges. Cassidy, a physician, has been increasingly critical of the administration’s approach to immunization policies.
Overton previously worked at the America First Policy Institute, a conservative think tank, where she authored papers critical of abortion rights and supported strict restrictions on medication abortion. Her nomination aligns with Trump administration initiatives on autism, vaccines, and reproductive health policies.
Agency Challenges and Confirmation Prospects
The FDA, responsible for regulating drugs, vaccines, and medical treatments, has faced criticism over low morale, staff departures, and perceived politicization. Overton’s confirmation would mark a significant shift in leadership, given her alignment with the administration’s policy priorities. However, her confirmation is not guaranteed, as Senate Democrats and some Republicans may raise concerns about her stances on reproductive rights and vaccine regulation.
The hearing will also consider the nomination of Trump’s surgeon general nominee, adding to the day’s agenda of health policy debates.